16 July, 2017
J P Morgan Chase & Co restated a "neutral" rating and set a GBX 4,500 ($58.29) target price on shares of AstraZeneca plc in a research note on Tuesday, May 23rd. The share last price represents downtick move of -9.02% in value from company's 52-Week high price and shows 26.77% above change in value from its 52-Week low price. The company's market cap is $82.91 Billion, and the average volume is 3.81 Million.
It closed at $1.1 lastly.
AstraZeneca PLC (AZN)'s average Piotroski F-Score: 4 during the last 7 years. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold.
An earnings forecast is an analyst's outlook for a company's future quarterly or annual earnings.
Relative Strength Index (RSI) for AstraZeneca PLC (AZN) is at 31.69.
About 1.62 million shares traded.
The stock of AstraZeneca plc (ADR) (NYSE:AZN) is a huge mover today! It has outperformed by 42.13% the S&P500.
AstraZeneca PLC was covered by a number of analysts recently, 2 rated the stock as Buy, 1 rated Hold, 0 rated sell and 0 gave an Underperform. Therefore 48% are positive. AstraZeneca plc (ADR) had 27 analyst reports since July 31, 2015 according to SRatingsIntel. The company was initiated on Friday, September 23 by Piperjaffray. HBSC downgraded the stock to "Hold" rating in Monday, February 8 report. The rating was downgraded by HBSC on Monday, February 8 to "Hold". On Friday, May 13 the stock rating was maintained by Deutsche Bank with "Buy". The expected AZN's profit could reach $1.09 billion giving the stock 18.98 P/E in the case that $0.44 earnings per share is reported. The firm has "Mkt Perform" rating given on Friday, December 16 by Raymond James. Shore Capital maintained the stock with "Hold" rating in Monday, June 12 report.
30/06/2017 - AstraZeneca had its "Buy" rating reiterated by analysts at Deutsche. The firm has "Outperform" rating by BNP Paribas given on Wednesday, April 13. During the same period a year ago, the company earned $0.95 EPS. After posting $0.99 EPS for the previous quarter, AstraZeneca plc (ADR)'s analysts now forecast -55.56 % negative EPS growth. Jefferies Group also issued estimates for Astrazeneca PLC's FY2018 earnings at $1.98 EPS, FY2019 earnings at $2.20 EPS, FY2020 earnings at $2.57 EPS and FY2021 earnings at $3.12 EPS.
Harvest Capital Strategies Llc increased Servicesource Intl Inc (NASDAQ:SREV) stake by 300,000 shares to 7.80M valued at $44.30M in 2016Q4. The mean rating score for this stock is at 2.90.
Investors sentiment decreased to 1.16 in Q4 2016. The dividend was $0.475 per share for the quarter or $1.90 on an annualized basis. 23 funds opened positions while 45 raised stakes. Silvercrest Asset Mngmt Group Incorporated Lc accumulated 0% or 11,000 shares. Tower Rech Capital Ltd Liability Corp (Trc) has 598 shares for 0% of their portfolio. Kennedy Mgmt owns 52,840 shares or 0.03% of their USA portfolio. American Int Gru reported 9,899 shares. Blackrock Inc has 0% invested in CU Bancorp (NASDAQ:CUNB) for 3,932 shares. Teachers Retirement Of The State Of Kentucky invested in 0% or 14,800 shares. Blackrock Investment Management Llc invested 0.01% of its portfolio in Briggs & Stratton Corporation (NYSE:BGG). 105,946 are owned by Geode Management. Parkside Bank invested in 0.01% or 10,521 shares.
(NYSE:AZN) shares saw heavy trading volume with 21,174K shares changing hands on Friday. Therefore 25% are positive. Barclays Capital maintained the shares of AZN in report on Monday, September 7 with "Underweight" rating. As per Tuesday, October 27, the company rating was maintained by Beaufort Securities.
12/05/2017 - AstraZeneca had its "Sell" rating reiterated by analysts at Shore Capital. Jefferies downgraded the stock to "Hold" rating in Tuesday, March 15 report.